StageZero Life Sciences Ltd Total Assets
StageZero Life Sciences Ltd total assets. Based on the latest financial reports, StageZero Life Sciences Ltd (SZLS) holds total assets worth CA$580.75K CAD (≈ $420.11K USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of StageZero Life Sciences Ltd for the company's overall valuation and market capitalisation.
Total Assets of StageZero Life Sciences Ltd (1998–2022)
Total assets of StageZero Life Sciences Ltd from 1998 to 2022. This chart illustrates how StageZero Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of StageZero Life Sciences Ltd for real-time trading data and today's change.
StageZero Life Sciences Ltd - Asset Composition Analysis
StageZero Life Sciences Ltd Total Assets Breakdown (December 2022)
StageZero Life Sciences Ltd total assets breakdown as of December 2022. StageZero Life Sciences Ltd's total assets of CA$580.75K consist of 38.0% current assets and 62.0% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 2.2% |
| Accounts Receivable | CA$31.24K | 4.5% |
| Inventory | CA$95.62K | 13.7% |
| Property, Plant & Equipment | CA$434.44K | 62.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore StageZero Life Sciences Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: StageZero Life Sciences Ltd's current assets represent 38.0% of total assets in 2022, a decrease from 60.1% in 1998.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2022, down from 57.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is property, plant & equipment at 62.0% of total assets.
StageZero Life Sciences Ltd Competitors by Total Assets
Key competitors of StageZero Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ICON Public Limited Company
F:IJF
|
Germany | €16.51 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
INTERGRATED DIA.H DL 025
F:8I8
|
Germany | €6.77 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
StageZero Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.04 | 0.19 |
| Quick Ratio | 0.02 | 0.03 | 0.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-10.09 Million | CA$-7.98 Million | CA$-3.45 Million |
StageZero Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between StageZero Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.94 |
| Latest Market Cap to Assets Ratio | 5.10 |
| Asset Growth Rate (YoY) | -93.4% |
| Total Assets | CA$700.65K |
| Market Capitalization | $3.58 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values StageZero Life Sciences Ltd's assets at a significant premium (5.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: StageZero Life Sciences Ltd's assets decreased by 93.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual total assets of StageZero Life Sciences Ltd from 1998 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | CA$700.65K ≈ $506.84K |
-93.42% |
| 2021-12-31 | CA$10.65 Million ≈ $7.70 Million |
+25.13% |
| 2020-12-31 | CA$8.51 Million ≈ $6.15 Million |
+333.01% |
| 2019-12-31 | CA$1.96 Million ≈ $1.42 Million |
-20.96% |
| 2018-12-31 | CA$2.49 Million ≈ $1.80 Million |
-7.71% |
| 2017-12-31 | CA$2.69 Million ≈ $1.95 Million |
-21.74% |
| 2016-12-31 | CA$3.44 Million ≈ $2.49 Million |
+501.57% |
| 2015-12-31 | CA$572.14K ≈ $413.88K |
-80.48% |
| 2014-12-31 | CA$2.93 Million ≈ $2.12 Million |
-2.09% |
| 2013-12-31 | CA$2.99 Million ≈ $2.17 Million |
-70.19% |
| 2012-12-31 | CA$10.04 Million ≈ $7.26 Million |
+146.56% |
| 2011-12-31 | CA$4.07 Million ≈ $2.95 Million |
-18.49% |
| 2010-12-31 | CA$5.00 Million ≈ $3.61 Million |
-21.45% |
| 2009-12-31 | CA$6.36 Million ≈ $4.60 Million |
+6.20% |
| 2008-12-31 | CA$5.99 Million ≈ $4.33 Million |
-68.54% |
| 2007-12-31 | CA$19.03 Million ≈ $13.77 Million |
-10.18% |
| 2006-12-31 | CA$21.19 Million ≈ $15.33 Million |
+141.43% |
| 2005-12-31 | CA$8.78 Million ≈ $6.35 Million |
-33.24% |
| 2004-12-31 | CA$13.15 Million ≈ $9.51 Million |
+109.42% |
| 2003-12-31 | CA$6.28 Million ≈ $4.54 Million |
+204.11% |
| 2002-12-31 | CA$2.06 Million ≈ $1.49 Million |
-15.76% |
| 2001-12-31 | CA$2.45 Million ≈ $1.77 Million |
+2.13% |
| 2000-12-31 | CA$2.40 Million ≈ $1.74 Million |
+6176.70% |
| 1999-12-31 | CA$38.23K ≈ $27.65K |
-77.27% |
| 1998-12-31 | CA$168.21K ≈ $121.68K |
-- |
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more